10:21 AM EDT, 07/18/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Thursday it has launched a new sprinkle formulation of Ingrezza capsules to treat adults with tardive dyskinesia and chorea associated with Huntington's disease, a neurodegenerative disorder.

Tardive dyskinesia and chorea are involuntary movement disorders and the availability of a drug that can be sprinkled on soft food reduces the burden of taking a pill for patients with these conditions, the drugmaker said.

The US Food and Drug Administration approved Ingrezza Sprinkle on April 30, the company said.

Shares of the company were up 2.2% in recent trading.

Price: 147.87, Change: +3.22, Percent Change: +2.22